Image credit- shutterstock
Hong Kong-based Insilico Medicine, a leader in clinical-stage generative AI for drug discovery, has announced a strategic collaboration agreement with Japanese pharma firm Takeda to use its proprietary end-to-end platform, Pharma.AI, to advance drug candidates across the company's therapeutic areas.
The collaboration is designed to identify clinically differentiated drug candidates for promising therapeutic targets. Using advanced generative models from the earliest stages of design, the teams aim to improve the quality of candidate molecules and optimize them to achieve best-in-class efficacy and safety criteria.
Under the agreement, Insilico will lead AI-driven discovery to identify molecules meeting predefined scientific and early development criteria, while Takeda will apply its global development capabilities to advance selected candidates through clinical validation.
Under the agreement, Insilico will receive approximately $60 million in project initiation fees, near-term payments and milestones, and is eligible for success-based preclinical, clinical, commercial and sales milestone payments that could bring the total deal value to approximately $600 million, plus tiered royalties on future sales.
The agreement grants Takeda exclusive worldwide rights to develop, manufacture, and commercialise novel therapeutics selected through the collaboration.
